Curaleaf Holdings (CURLF) Net Cash Flow (2019 - 2024)
Curaleaf Holdings (CURLF) posted quarterly Net Cash Flow of $15.5 million for Q4 2024, up 165.12% year-over-year from $5.9 million in Q1 2024, and up 537.11% quarter-over-quarter from $2.4 million in Q3 2024.
Curaleaf Holdings (CURLF) Net Cash Flow (2019 - 2024) Analysis & Trends
Curaleaf Holdings' Net Cash Flow history runs 6 years deep, the most recent figure standing at $15.5 million for Q4 2024.
- In Q4 2024, Net Cash Flow rose 165.12% year-over-year to $15.5 million; the TTM figure through Sep 2025 stood at $15.5 million (up 165.56% YoY), while the FY2025 annual figure was -$6.1 million, down 139.05% from the prior year.
- Net Cash Flow for Q4 2024 stood at $15.5 million, up from $2.4 million in the prior quarter.
- The five-year high for Net Cash Flow was $47.4 billion in Q2 2023, with the low at -$47.5 billion in Q1 2023.
- The 5-year median for Net Cash Flow is $1.2 million (2020), against an average of $13.9 million.
- Peak annual rise in Net Cash Flow reached 246238.05% in 2023, while the deepest fall reached 116680.32% in 2023.
- Curaleaf Holdings' Net Cash Flow stood at -$4.1 million in 2020, then slumped by 355.73% to -$18.7 million in 2021, then jumped by 280.6% to $33.8 million in 2022, then tumbled by 170.59% to -$23.9 million in 2023, then jumped by 165.12% to $15.5 million in 2024.
- Business Quant data shows CURLF's Net Cash Flow at $15.5 million in Q4 2024, $2.4 million in Q3 2024, and -$41.9 billion in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | -81.00 Mn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | -458.00 Mn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | -881.03 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 523.50 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -912.40 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 64.40 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 93.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Curaleaf Holdings | 2.48 Bn | 2.38 Bn | 169.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 15.54 Mn |
| Dec 31, 2024 | 15.54 Mn |
| Sep 30, 2024 | 2.44 Mn |
| Sep 30, 2024 | 2.44 Mn |
| Jun 30, 2024 | -41.93 Bn |
| Jun 30, 2024 | -41.93 Bn |
| Mar 31, 2024 | 41.93 Bn |
| Mar 31, 2024 | 41.93 Bn |
| Dec 31, 2023 | -23.86 Mn |
| Dec 31, 2023 | -23.86 Mn |
| Sep 30, 2023 | 31.71 Mn |
| Sep 30, 2023 | 31.71 Mn |
| Jun 30, 2023 | 47.40 Bn |
| Jun 30, 2023 | 47.40 Bn |
| Mar 31, 2023 | -47.48 Bn |
| Mar 31, 2023 | -47.48 Bn |
| Dec 31, 2022 | 33.80 Mn |
| Dec 31, 2022 | 33.80 Mn |
| Sep 30, 2022 | -26.01 Mn |
| Sep 30, 2022 | -26.01 Mn |